Alloplex Biotherapeutics today announced the opening of the third site in its first-in-human clinical trial of SUPLEXA: Southern Oncology Cancer Research Unit ‘SOCRU’. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived from patient peripheral blood mononuclear cel...
Topic: Company News
-
December 15, 2022
Alloplex opens third prestigious site for SUPLEXA-101 first-in-class cellular therapy trial in oncology patients
Southern Oncology Clinical Research Unit in Adelaide joins Cancer Research SA, also in Adelaide, and Gallipoli Medical Research Foundation of Brisbane for the Phase 1 trial of Alloplex Biotherapeutics' autologous SUPLEXA cell immunotherapy.
Read More -
April 29, 2022
Alloplex Biotherapeutics announces opening of first clinical trial site
Phase 1 trial of autologous SUPLEXA cell immunotherapy, commences in Adelaide South Australia
Alloplex Biotherapeutics announced today the site opening for its first-in-human clinical trial of SUPLEXA. SUPLEXA therapy is a highly-differentiated, autologous, non-engineered, multi-cellular therapy derived, from patient peripheral blood mononuclear cells. This Phase 1 is a first-in-human, open-label single agent b...
Read More -
March 29, 2022
Alloplex appoints CLL expert Dr. Jennifer Brown to its scientific advisory board
Dr. Brown, the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts, is internationally known for her clinical-trans...
Read More -
January 17, 2022
Human Research Ethics Committee (HREC) in Australia approves the start of the first SUPLEXA Phase 1 Clinical Trial
Alloplex Biotherapeutics, Inc. (‘Alloplex’) – a private cellular therapeutics company dedicated to developing and commercializing a global first-in-class cellular therapeutic in oncology – today announced that the Human Research Ethics Committee (HREC) in Australia has approved the clinical trial application fo...
Read More -
December 15, 2021
Hackensack Meridian Health’s Bear’s Den supports company developing novel way to ‘train’ patients’ own white blood cells
Alloplex Biotherapeutic and Hackensack Meridian Health announce equity investment.
Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, is proud to announce its support of the clinical development of a highly-differentiated immuno-oncology platform by Boston-based Alloplex Biotherapeutics, Inc.
Read More -
December 8, 2021
Alloplex appoints Dr. Andre Goy to its scientific advisory board
Dr. Goy is Physician in Chief of Hackensack Meridian Health Oncology Care Transformation Service; Chairman & Chief Physician Officer of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center; Lydia Pfund Chair for Lymphoma; Academic Chairman Oncology at Hackensack Meridian School of Medicine at Seton...
Read More -
November 1, 2021
Alloplex forms corporate board
Appoints two members: Dr. Sung-Wuk Kim and TaeOh ‘Jared’ Chung.
Alloplex Biotherapeutics Inc. announced the formation of a Corporate Board today: at a pivotal juncture in the organization’s development as it is poised to embark on its first-in-human clinical trial.
Read More -
September 29, 2021
A tribute to Dr. Martin ‘Mac’ Cheever
It is with great sadness that we learned this week that Dr. Mac Cheever died of complications from what was a planned cardiac surgery earlier this year. Mac’s achievements over 40 years at the Fred Hutchinson Cancer Research Center were well known and admired across the immunology community.
Read More